242 related articles for article (PubMed ID: 36271471)
1. Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial.
Khan AA; Rubin MR; Schwarz P; Vokes T; Shoback DM; Gagnon C; Palermo A; Marcocci C; Clarke BL; Abbott LG; Hofbauer LC; Kohlmeier L; Pihl S; An X; Eng WF; Smith AR; Ukena J; Sibley CT; Shu AD; Rejnmark L
J Bone Miner Res; 2023 Jan; 38(1):14-25. PubMed ID: 36271471
[TBL] [Abstract][Full Text] [Related]
2. PaTH Forward: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism.
Khan AA; Rejnmark L; Rubin M; Schwarz P; Vokes T; Clarke B; Ahmed I; Hofbauer L; Marcocci C; Pagotto U; Palermo A; Eriksen E; Brod M; Markova D; Smith A; Pihl S; Mourya S; Karpf DB; Shu AD
J Clin Endocrinol Metab; 2022 Jan; 107(1):e372-e385. PubMed ID: 34347093
[TBL] [Abstract][Full Text] [Related]
3. Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial.
Rejnmark L; Gosmanova EO; Khan AA; Makita N; Imanishi Y; Takeuchi Y; Sprague S; Shoback DM; Kohlmeier L; Rubin MR; Palermo A; Schwarz P; Gagnon C; Tsourdi E; Zhao C; Makara MA; Ominsky MS; Lai B; Ukena J; Sibley CT; Shu AD
Adv Ther; 2024 Jun; 41(6):2500-2518. PubMed ID: 38691316
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Double-Blind Placebo-Controlled First-In-Human Phase 1 Trial of TransCon PTH in Healthy Adults.
Karpf DB; Pihl S; Mourya S; Mortensen E; Kovoor E; Markova D; Leff JA
J Bone Miner Res; 2020 Aug; 35(8):1430-1440. PubMed ID: 32212275
[TBL] [Abstract][Full Text] [Related]
5. Design and Preclinical Development of TransCon PTH, an Investigational Sustained-Release PTH Replacement Therapy for Hypoparathyroidism.
Holten-Andersen L; Pihl S; Rasmussen CE; Zettler J; Maitro G; Baron J; Heinig S; Hoffmann E; Wegge T; Krusch M; Faltinger F; Killian S; Sprogoe K; Karpf DB; Breinholt VM; Cleemann F
J Bone Miner Res; 2019 Nov; 34(11):2075-2086. PubMed ID: 31291476
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of PTH 1-34 and 1-84 Therapy in Chronic Hypoparathyroidism: A Meta-Analysis of Prospective Trials.
Puliani G; Hasenmajer V; Simonelli I; Sada V; Pofi R; Minnetti M; Cozzolino A; Napoli N; Pasqualetti P; Gianfrilli D; Isidori AM
J Bone Miner Res; 2022 Jul; 37(7):1233-1250. PubMed ID: 35485213
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study.
Mannstadt M; Clarke BL; Vokes T; Brandi ML; Ranganath L; Fraser WD; Lakatos P; Bajnok L; Garceau R; Mosekilde L; Lagast H; Shoback D; Bilezikian JP
Lancet Diabetes Endocrinol; 2013 Dec; 1(4):275-83. PubMed ID: 24622413
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Oral Human Parathyroid Hormone (1-34) in Hypoparathyroidism: An Open-Label Study.
Ish-Shalom S; Caraco Y; Khazen NS; Gershinsky M; Szalat A; Schwartz P; Arbit E; Galitzer H; Tang JC; Burshtein G; Rothner A; Raskin A; Blum M; Fraser WD
J Bone Miner Res; 2021 Jun; 36(6):1060-1068. PubMed ID: 33666947
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Hypoparathyroidism by Re-Establishing the Effects of Parathyroid Hormone.
Rejnmark L
Endocrinol Metab (Seoul); 2024 Apr; 39(2):262-266. PubMed ID: 38572533
[TBL] [Abstract][Full Text] [Related]
10. PTH(1-34) for Surgical Hypoparathyroidism: A 2-Year Prospective, Open-Label Investigation of Efficacy and Quality of Life.
Palermo A; Santonati A; Tabacco G; Bosco D; Spada A; Pedone C; Raggiunti B; Doris T; Maggi D; Grimaldi F; Manfrini S; Vescini F
J Clin Endocrinol Metab; 2018 Jan; 103(1):271-280. PubMed ID: 29099939
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study.
Clarke BL; Kay Berg J; Fox J; Cyran JA; Lagast H
Clin Ther; 2014 May; 36(5):722-36. PubMed ID: 24802860
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment of 12 children with chronic hypoparathyroidism: a randomized trial comparing synthetic human parathyroid hormone 1-34 versus calcitriol and calcium.
Winer KK; Sinaii N; Reynolds J; Peterson D; Dowdy K; Cutler GB
J Clin Endocrinol Metab; 2010 Jun; 95(6):2680-8. PubMed ID: 20392870
[TBL] [Abstract][Full Text] [Related]
13. Parathyroid Hormone Therapy for Managing Chronic Hypoparathyroidism: A Systematic Review and Meta-Analysis.
Yao L; Li J; Li M; Lin C; Hui X; Tamilselvan D; Kandi M; Sreekanta A; Makhdami N; Ali DS; Dandurand K; Yang K; Bilezikian JP; Brandi ML; Clarke BL; Mannstadt M; Rejnmark L; Khan AA; Guyatt G
J Bone Miner Res; 2022 Dec; 37(12):2654-2662. PubMed ID: 36385517
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism.
Mannstadt M; Clarke BL; Bilezikian JP; Bone H; Denham D; Levine MA; Peacock M; Rothman J; Shoback DM; Warren ML; Watts NB; Lee HM; Sherry N; Vokes TJ
J Clin Endocrinol Metab; 2019 Nov; 104(11):5136-5147. PubMed ID: 31369089
[TBL] [Abstract][Full Text] [Related]
15. Management of Hypoparathyroidism.
Khan AA; Guyatt G; Ali DS; Bilezikian JP; Collins MT; Dandurand K; Mannstadt M; Murphy D; M'Hiri I; Rubin MR; Sanders R; Shrayyef M; Siggelkow H; Tabacco G; Tay YD; Van Uum S; Vokes T; Winer KK; Yao L; Rejnmark L
J Bone Miner Res; 2022 Dec; 37(12):2663-2677. PubMed ID: 36161671
[TBL] [Abstract][Full Text] [Related]
16. PTH(1-34) for Surgical Hypoparathyroidism: A Prospective, Open-Label Investigation of Efficacy and Quality of Life.
Santonati A; Palermo A; Maddaloni E; Bosco D; Spada A; Grimaldi F; Raggiunti B; Volpe R; Manfrini S; Vescini F;
J Clin Endocrinol Metab; 2015 Sep; 100(9):3590-7. PubMed ID: 26196949
[TBL] [Abstract][Full Text] [Related]
17. Parathyroid Hormone Replacement Therapy in Hypoparathyroidism: A Meta-Analysis.
Liu XX; Zhu XY; Mei GH
Horm Metab Res; 2016 Jun; 48(6):377-83. PubMed ID: 27254756
[TBL] [Abstract][Full Text] [Related]
18. The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study.
Sikjaer T; Rejnmark L; Rolighed L; Heickendorff L; Mosekilde L;
J Bone Miner Res; 2011 Oct; 26(10):2358-70. PubMed ID: 21773992
[TBL] [Abstract][Full Text] [Related]
19. AN OPEN-LABEL EXTENSION STUDY OF PARATHYROID HORMONE RHPTH(1-84) IN ADULTS WITH HYPOPARATHYROIDISM.
Lakatos P; Bajnok L; Lagast H; Valkusz Z
Endocr Pract; 2016 May; 22(5):523-32. PubMed ID: 26684150
[TBL] [Abstract][Full Text] [Related]
20. PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment.
Sikjaer T; Amstrup AK; Rolighed L; Kjaer SG; Mosekilde L; Rejnmark L
J Bone Miner Res; 2013 Oct; 28(10):2232-43. PubMed ID: 23649554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
